Echo Therapeutics Inc fka ECTE

[starbuxsux]

Echo Therapeutics to Present at the Canaccord Genuity 2012 Medical Technology & Diagnostics Forum

Nov 29, 2012 07:50:00 (ET)

PHILADELPHIA, Nov. 29, 2012 /PRNewswire via COMTEX/ -- Echo Therapeutics, Inc. , a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics will present at the Canaccord Genuity 2012 Medical Technology & Diagnostics Forum.

Dr. Mooney will make a corporate presentation to prospective corporate partners and investors at 8:30 AM EST on Tuesday, December 4th in New York City.

At the time of the presentation, a live audio webcast of Dr. Mooney's presentation will be available in the Events section of the company's website at www.echotx.com . A replay of the webcast will also be available after the conclusion of the presentation for a period of 30 days.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system. Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care. Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:Christine H. OlimpioDirector, Investor Relations and Corporate Communications [phone] [e-mail]

Connect With Us:- Visit our website at www.echotx.com - Follow us on Twitter at www.twitter.com/echotx- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.